Timber Creek Capital Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Timber Creek Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-200	Closed	-$13K	–	102
2015 Q4	$13K	Buy	+200	New	+$12.4K	0.01%	85

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Timber Creek Capital Management's TEVA Position: Q1 2016 in Review

Timber Creek Capital Management sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q1 2016, closing a stake of 200 shares — an estimated $13K sold.

Timber Creek Capital Management first reported a position in TEVA in Q4 2015 and held it in 1 quarter. The position peaked at $13K in Q4 2015. 837 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

Timber Creek Capital Management reported no remaining Teva Pharmaceutical Industries Limited position as of Q1 2016 after selling out during the quarter.
Timber Creek Capital Management sold 200 Teva Pharmaceutical Industries Limited shares in Q1 2016, an estimated $13K.
Timber Creek Capital Management first reported a position in Teva Pharmaceutical Industries Limited in Q4 2015 and held it in 1 quarter.
Timber Creek Capital Management's Teva Pharmaceutical Industries Limited position peaked at $13K in Q4 2015.
837 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q1 2016.

Based on Timber Creek Capital Management's 13F filing for Q1 2016, filed 11 May 2016.